Pulmonary vascular disease in the developing world

Circulation

Volumn 118, Issue 17, 2008, Pages 1758-1766

  Butrous, Ghazwan ^a   Ghofrani, Hossein Ardeschir ^b,c   Grimminger, Friedrich ^b,c  

^a UNIVERSITY OF KENT   (United Kingdom)

^b UNIVERSITY HOSPITAL GIESSEN   (Germany)

^c Pulmonary Vascular Research Institute   (United Kingdom)

Author keywords

Epidemiology; Heart diseases; Hypertension, pulmonary; Hypoxia; Infection

Indexed keywords

ANTIRETROVIRUS AGENT; ARGININE; ENDOTHELIN RECEPTOR ANTAGONIST; OXAMNIQUINE; PHOSPHODIESTERASE V INHIBITOR; PRAZIQUANTEL; PROSTANOIC ACID;

BRAZIL; CLONORCHIS SINENSIS; CYTOKINE PRODUCTION; DEVELOPING COUNTRY; DISEASE ASSOCIATION; DRUG EFFICACY; ENDEMIC DISEASE; HEART DISEASE; HEART MUSCLE FIBROSIS; HELMINTHIASIS; HEMOLYTIC ANEMIA; HERPES; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOMODULATION; LIFE CYCLE; LUNG CIRCULATION; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; PULMONARY VASCULAR DISEASE; REVIEW; SCHISTOSOMA HEMATOBIUM; SCHISTOSOMA JAPONICUM; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS; THORAX RADIOGRAPHY; WUCHERERIA BANCROFTI; ANIMAL; LUNG DISEASE; PATHOLOGY; STATISTICS; VASCULAR DISEASE;

ANIMALS; DEVELOPING COUNTRIES; HUMANS; LUNG DISEASES; SCHISTOSOMIASIS; VASCULAR DISEASES;

EID: 55449118686     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.107.727289     Document Type: Review

References (99)

1. Gryseels B, Polman K, Clerinx J, Kestens L. Human schistosomiasis. Lancet. 2006;368:1106-1118.
2. Chitsulo L, Engels D, Montresor A, Savioli L. The global status of schistosomiasis and its control. Acta Trop. 2000;77:41-51.
3. Patz JA, Graczyk TK, Geller N, Vittor AY. Effects of environmental change on emerging parasitic diseases. Int J Parasitol. 2000;30:1395-1405.
4. Schwartz E. Pulmonary schistosomiasis. Clin Chest Med. 2002;23:433-443.
5. de Jesus AR, Silva A, Santana LB, Magalhes A, de Jesus AA, de Almeida RP, Rgo MA, Burattini MN, Pearce EJ, Carvalho EM. Clinical and immunologic evaluation of 31 patients with acute schistosomiasis mansoni. J Infect Dis. 2002;185:98-105.
6. Morris W, Knauer CM. Cardiopulmonary manifestations of schistosomiasis. Semin Respir Infect. 1997;12:159-170.
7. Akoun G, Berkman M, Gallouedec C, Brocard H. [Precapillary pulmonary arterial hypertension and chronic pulmonary heart disease due to bilharziasis [in French]. Nouv Presse Med. 1972;1:1100.
8. Bertrand E, Dalger J, Ramiara JP, Renambot J, Attia Y. Bilharzial pulmonary arterial hypertension: clinical and hemodynamic study in 37 patients [in French]. Arch Mal Coeur Vaiss. 1978;71:216-221.
9. Klotz F, Hovette P, Mbaye PS, Fall F, Thiam M, Cloatre G. Pulmonary manifestations of schistosomiasis [in French]. Rev Pneumol Clin. 1998;54:353-358.
10. Bertrand E, Renambot J, Chauvet J, Ekra A, Clerc G. Study of 20 cases of apparently primary pulmonary arterial hypertension [in French]. Arch Mal Coeur Vaiss. 1977;70:191-199.
11. Aderaye G. Causes and clinical characteristics of chronic cor-pulmonale in Ethiopia. East Afr Med J. 2004;81:202-206.
12. De Leon EP, Pardo de Tavera M. Pulmonary schistosomiasis in the Philippines. Dis Chest. 1968;53:154-161.
13. Boure P, Piveteau J, Gerbal JL, Halpen G. Pulmonary arterial hypertension due to bilharziasis. Apropos of a case due to Schistosoma haematobium having been cured by praziquantel [in French]. Bull Soc Pathol Exot. 1990;83:66-71.
14. Watt G, Long GW, Calubaquib C, Ranoa CP. Cardiopulmonary involvement rare in severe Schistosoma japonicum infection. Trop Geogr Med. 1986;38:233-239.
15. Ostrea EM, Marcelo FB. Relationship between pulmonary schistosomiasis japonicum and cor pulmonale: a pathologic study. Acta Med Philipp. 1965;2:68-77.
16. Barbosa MM, Lamounier JA, Oliveira EC, Souza MV, Marques DS, Silva AA, Lambertucci J. Pulmonary hypertension in schistosomiasis mansoni. Trans R Soc Trop Med Hyg. 1996;90:663-665.
17. Andrade ZA, Bina JC. The changing pattern of pathology due to Schistosoma mansoni infection. Mem Inst Oswaldo Cruz. 1985;80:363-366.
18. Lambertucci JR, Serufo JC, Gerspacher-Lara R, Rayes AAM, Teixeira R, Nobre V, Antunes CMF. Schistosoma mansoni: assessment of morbidity before and after control. Acta Trop. 2000;77:101-109.
19. Lapa MS, Ferreira EVM, Jardim C, Martins Bdo C, Arakaki JS, Souza R. Clinical characteristics of pulmonary hypertension patients in two reference centers in the city of Sao Paulo. Rev Assoc Med Bras. 2006;52:139-143.
20. El Hawey AM, Rakaiby AA, Negm IA, Abdel Maged AI. Assessment of left ventricular function by Doppler echocardiography in Egyptian bilharzial patients with or without pulmonary hypertension. J Egypt Soc Parasitol. 1992;22:629-642.
21. Pedroso ERP, Lambertucci JR, Greco DB, da Costa Rocha MO, Ferreira CS, Raso P. Pulmonary schistosomiasis mansoni: post-treatment pulmonary clinical-radiological alterations in patients in the chronic phase: a double-blind study. Trans R Soc Trop Med Hyg. 1987;81:778-781.
22. El-Ahwany EG, Nosseir MM, Aly IR. Immunomodulation of pulmonary and hepatic granulomatous response in mice immunized with purified lung-stage schistosomulae antigen. J Egypt Soc Parasitol. 2006;36:335-350.
23. Cheever AW, Andrade ZA. Pathological lesions associated with Schistosoma mansoni infection in man. Trans R Soc Trop Med Hyg. 1967;61:626-639.
24. de Cleva R, Herman P, Pugliese V, Zilberstein B, Saad WA, Gama-Rodrigues JJ. Fatal pulmonary hypertension after distal splenorenal shunt in schistosomal portal hypertension. World J Gastroenterol. 2004;10:1836-1837.
25. Wilson MS, Mentink-Kane MM, Pesce JT, Ramalingam TR, Thompson R, Wynn TA. Immunopathology of schistosomiasis. Immunol Cell Biol. 2007;85:148-154.
26. Boros DL, Whitfield JR. Enhanced Th1 and dampened Th2 responses synergize to inhibit acute granulomatous and fibrotic responses in murine schistosomiasis mansoni. Infect Immun. 1999;67:1187-1193.
27. Chiu BC, Freeman CM, Stolberg VR, Komuniecki E, Lincoln PM, Kunkel SL, Chensue SW. Cytokine-chemokine networks in experimental mycobacterial and schistosomal pulmonary granuloma formation. Am J Respir Cell Mol Biol. 2003;29:106-116.
28. Dorfmuller P, Perros F, Balabanian K, Humbert M. Inflammation in pulmonary arterial hypertension. Eur Respir J. 2003;22:358-363.
29. Witzenrath M, Ahrens B, Kube SM, Hocke AC, Rosseau S, Hamelmann E, Suttorp N, Schutte H. Allergic lung inflammation induces pulmonary vascular hyperresponsiveness. Eur Respir J. 2006;28:370-377.
30. Esmon CT. Coagulation and inflammation. J Endotoxin Res. 2003;9:192-198.
31. Lejoly-Boisseau H, Blann AD, Seigneur M, Tribouley-Duret J, Tribouley J, Boisseau MR. Endothelium activation related increase of soluble intercellular adhesion molecule-1 in human schistosomiasis: lack of correlation with serology. Eur J Clin Invest. 1996;26:522-523.
32. Hesse M, Modolell M, La Flamme AC, Schito M, Fuentes JM, Cheever AW, Pearce EJ, Wynn TA. Differential regulation of nitric oxide synthase-2 and arginase-1 by type 1/type 2 cytokines in vivo: granulomatous pathology is shaped by the pattern of L-arginine metabolism. J Immunol. 2001;167:6533-6544.
33. Zhu Z, Homer RJ, Wang Z, Chen Q, Geba GP, Wang J, Zhang Y, Elias JA. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest. 1999;103:779-788.
34. Lepetit H, Eddahibi S, Fadel E, Frisdal E, Munaut C, Noel A, Humbert M, Adnot S, D'Ortho MP, Lafuma C. Smooth muscle cell matrix metalloproteinases in idiopathic pulmonary arterial hypertension. Eur Respir J. 2005;25:834-842.
35. Hecker M, Kwapiszewska G, Zakrzewicz A, Marsh L, Seay U, Sedding D, Weissmann N, Klepetko W, Seeger W, Eickelberg O. The interleukin 13 receptor system: a novel pathogenetic mechanism in pulmonary arterial hypertension. Pneumologie. 2007;61:A18. Abstract.
36. Teng X, Li D, Champion HC, Johns RA. FIZZ1/RELM{alpha}, a novel hypoxia-induced mitogenic factor in lung with vasoconstrictive and angiogenic properties. Circ Res. 2003;92:1065-1067.
37. Yamaji-Kegan K, Su Q, Angelini DJ, Champion HC, Johns RA. Hypoxia-induced mitogenic factor has proangiogenic and proinflammatory effects in the lung via VEGF and VEGF receptor-2. Am J Physiol Lung Cell Mol Physiol. 2006;291:L1159-L1168.
38. Voelkel NF, Vandivier RW, Tuder RM. Vascular endothelial growth factor in the lung. Am J Physiol Lung Cell Mol Physiol. 2006;290:L209-L221.
39. Michelakis ED. Spatio-temporal diversity of apoptosis within the vascular wall in pulmonary arterial hypertension: heterogeneous BMP signaling may have therapeutic implications. Circ Res. 2006;98:172-175.
40. Salama M, El-Kholy G, Abd El-Haleem S, Elzamarany E, Abou Freikha M, Elwan N, El-Masry M, Al-Bacil A, Elhendy A. Serum soluble Fas in patients with Schistosomal cor pulmonale. Respiration. 2003;70:574-578.
41. Warren KS. Experimental pulmonary schistosomiasis. Trans R Soc Trop Med Hyg. 1964;58:228-233.
42. de Cleva R, Herman P, Pugliese V, Zilberstein B, Saad WA, Rodrigues JJ, Laudanna AA. Prevalence of pulmonary hypertension in patients with hepatosplenic Mansonic schistosomiasis: prospective study. Hepatogastroenterology. 2003;50:2028-2030.
43. Mwanakasale V, Vounatsou P, Sukwa TY, Ziba M, Ernest A, Tanner M. Interactions between Schistosoma haematobium and human immunodeficiency virus type 1: the effects of coinfection on treatment outcomes in rural Zambia. Am J Trop Med Hyg. 2003;69:420-428.
44. Walloopillai NJ. Primary pulmonary hypertension, an unexplained epidemic in Sri Lanka. Pathol Microbiol (Basel). 1975;43:248-250.
45. Obeyesekere I, Peiris D. Pulmonary hypertension and filariasis. Br Heart J. 1974;36:676-681.
46. Cockshott P. Cardiac disease in the tropics. In: Palmer PES, Reeder MM, eds. The Imaging of Tropical Diseases: With Epidemiological, Pathological, and Clinical Correlation. New York, NY: Springer; 2001.
47. Lai KS, McFadzean AJ, Yeung R. Microembolic pulmonary hypertension in pyogenic cholangitis. BMJ. 1968;1:22-24.
48. Kim KK, Factor SM. Membranoproliferative glomerulonephritis and plexogenic pulmonary arteriopathy in a homosexual man with acquired immunodeficiency syndrome. Hum Pathol. 1987;18:1293-1296.
49. Petrosillo N, Chinello P, Cicalini S. Pulmonary hypertension in individuals with HIV infection. AIDS. 2006;20:2128-2129.
50. Opravil M, Pechere M, Speich R, Joller-Jemelka HI, Jenni R, Russi EW, Hirschel B, Luthy R. HIV-associated primary pulmonary hypertension: a case control study: Swiss HIV Cohort Study. Am J Respir Crit Care Med. 1997;155:990-995.
51. Sitbon O, Lascoux-Combe C, Sereni D, Raffi F, Yeni P, Gressin V, Clerson P, Simonneau G. Prevalence of pulmonary arterial hypertension in HIV positive outpatients in the HAART era. Eur Respir J. 2006;28(suppl):545s.
52. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, Yaici A, Weitzenblum E, Cordier J-F, Chabot F, Dromer C, Pison C, Reynaud-Gaubert M, Haloun A, Laurent M, Hachulla E, Simonneau G. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006;173:1023-1030.
53. Ntsekhe M, Hakim J. Impact of human immunodeficiency virus infection on cardiovascular disease in Africa. Circulation. 2005;112:3602-3607.
54. Mehta NJ, Khan IA, Mehta RN, Sepkowitz DA. HIV-related pulmonary hypertension: analytic review of 131 cases. Chest. 2000;118:1133-1141.
55. Cool CD, Kennedy D, Voelkel NF, Tuder RM. Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunodeficiency virus infection. Hum Pathol. 1997;28:434-442.
56. Nunes H, Humbert M, Sitbon O, Morse JH, Deng Z, Knowles JA, Le Gall C, Parent F, Garcia G, Herve P, Barst RJ, Simonneau G. Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med. 2003;167:1433-1439.
57. Schott R, Chaouat A, Lang JM, Weitzenblum E. Pulmonary hypertension in human immunodeficiency virus infection. Eur Respir J. 2002;20(suppl):443s. Abstract.
58. Mette SA, Palevsky HI, Pietra GG, Williams TM, Brader E, Prestipino AJ, Patrick AM, Wirth JA. Primary pulmonary hypertension in association with human immunodeficiency virus infection: a possible viral etiology for some forms of hypertensive pulmonary arteriopathy. Am Rev Respir Dis. 1992;145:1196-1200.
59. + T cells. FEBS Lett. 1996;393:93-96.
60. Marecki JC, Cool CD, Parr JE, Beckey VE, Luciw PA, Tarantal AF, Carville A, Shannon RP, Cota-Gomez A, Tuder RM, Voelkel NF, Flores SC. HIV-1 Nef is associated with complex pulmonary vascular lesions in shiv-nef-infected macaques. Am J Respir Crit Care Med. 2006;174:437-445.
61. Humbert M, Monti G, Fartoukh M, Magnan A, Brenot F, Rain B, Capron F, Galanaud P, Duroux P, Simonneau G. Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. Eur Respir J. 1998;11:554-559.
62. Aguilar RV, Farber HW. Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension. Am J Respir Crit Care Med. 2000;162:1846-1850.
63. Sitbon O, Gressin V, Speich R, Macdonald PS, Opravil M, Cooper DA, Fourme T, Humbert M, Delfraissy J-F, Simonneau G. Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med. 2004;170:1212-1217.
64. Wong AR, Rasool AH, Abidin NZ, Noor AR, Quah BS. Sildenafil as treatment for human immunodeficiency virus-related pulmonary hypertension in a child. J Paediatr Child Health. 2006;42:147-148.
65. Cool CD, Rai PR, Yeager ME, Hernandez-Saavedra D, Serls AE, Bull TM, Geraci MW, Brown KK, Routes JM, Tuder RM, Voelkel NF. Expression of human herpesvirus 8 in primary pulmonary hypertension. N Engl J Med. 2003;349:1113-1122.
66. Henke-Gendo C, Mengel M, Hoeper MM, Alkharsah K, Schulz TF. Absence of Kaposi's sarcoma-associated herpesvirus in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med. 2005;172:1581-1585.
67. Katano H, Ito K, Shibuya K, Saji T, Sato Y, Sata T. Lack of human herpesvirus 8 infection in lungs of Japanese patients with primary pulmonary hypertension. J Infect Dis. 2005;191:743-745.
68. Galambos C, Montgomery J, Jenkins FJ. No role for Kaposi sarcoma-associated herpesvirus in pediatric idiopathic pulmonary hypertension. Pediatr Pulmonal. 2006;41:122.
69. Rimar D, Rimar Y, Keynan Y. Human herpesvirus-8: beyond Kaposi's. Isr Med Assoc J. 2006;8:489-493.
70. Mohanna S, Ferrufino JC, Sanchez J, Bravo F, Gotuzzo E. Epidemiological and clinical characteristics of classic Kaposi's sarcoma in Peru. J Am Acad Dermatol. 2005;53:435-441.
71. Collins FS, Orringer EP. Pulmonary hypertension and cor pulmonale in the sickle hemoglobinopathies. Am J Med. 1982;73:814-821.
72. Gladwin MT, Sachdev V, Jison ML, Shizukuda Y, Plehn JF, Minter K, Brown B, Coles WA, Nichols JS, Ernst I, Hunter LA, Blackwelder WC, Schechter AN, Rodgers GP, Castro O, Ognibene FP. Pulmonary hypertension as a risk factor for death in patients wim sickle cell disease. N Engl J Med. 2004;350:886-895.
73. Ataga KI, Moore CG, Jones S, Olajide O, Strayhorn D, Hinderliter A, Orringer EP. Pulmonary hypertension in patients with sickle cell disease: a longitudinal study. Br J Haematol. 2006;134:109-115.
74. Aessopos A, Farmakis D. Pulmonary hypertension in beta-thalassemia. Ann NY Acad Sci. 2005;1054:342-349.
75. Morris CR, Kuypers FA, Kato GJ, Lavrisha L, Larkin S, Singer T, Vichinsky EP. Hemolysis-associated pulmonary hypertension in thalassemia. Ann N Y Acad Sci. 2005;1054:481-485.
76. Smedema JP, Louw VJ. Pulmonary arterial hypertension after splenectomy for hereditary spherocytosis. Cardiovasc J S Afr. 2007;18:84-89.
77. Monsuez JJ, Auperin I, Vittecoq D, Heshmati F. Pulmonary hypertension associated with thrombotic thrombocytopaenic purpura in AIDS patients. Eur Heart J. 1997;18:1036-1037.
78. Labrune P, Zittoun J, Duvaltier I, Trioche P, Marquet J, Niaudet P. Odievre M. Haemolytic uraemic syndrome and pulmonary hypertension in a patient with methionine synthase deficiency. Eur J Pediatr. 1999;158:734-739.
79. Hsu LL, Champion HC, Campbell-Lee SA, Bivalacqua TJ, Manci EA, Diwan BA, Schimel DM, Cochard AE, Wang X, Schechter AN, Noguchi CT, Gladwin MT. Hemolysis in sickle cell mice causes pulmonary hypertension due to global impairment in nitric oxide bioavailability. Blood. 2007;109:3088-3098.
80. Weatherall DJ, Clegg JB. Inherited haemoglobin disorders: an increasing global health problem. Bull World Health Org. 2001;79:704-712.
81. Morris CR, Morris SM Jr, Hagar W, van Warmerdam J, Claster S, Kepka-Lenhart D, Machado L, Kuypers FA, Vichinsky EP. Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease? Am J Respir Crit Care Med. 2003;168:63-69.
82. Machado RF, Martyr S, Kato GJ, Barst RJ, Anthi A, Robinson MR, Hunter L, Coles W, Nichols J, Hunter C. Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension. Br J Haematol. 2005;130:445-453.
83. Penaloza D, Arias-Stella J. The heart and pulmonary circulation at high altitudes: healthy highlanders and chronic mountain sickness. Circulation. 2007;115:1132-1146.
84. Chen Q-H, Ge R-L, Wang X-Z, Chen H-X, Wu T-Y, Kobayashi T, Yoshimura K. Exercise performance of Tibetan and Han adolescents at altitudes of 3,417 and 4,300 m. J Appl Physiol. 1997;83:661-667.
85. Groves BM, Droma T, Sutton JR, McCullough RG, McCullough RE, Zhuang J, Rapmund G, Sun S, Janes C, Moore LG. Minimal hypoxic pulmonary hypertension in normal Tibetans at 3,658 m. J Appl Physiol. 1993;74:312-318.
86. Beall CM. Colloquium papers: two routes to functional adaptation: Tibetan and Andean high-altitude natives. Proc Natl Acad Sci U S A. 2007;104:8655-8660.
87. Aldashev AA, Sarybaev AS, Sydykov AS, Kalmyrzaev BB, Kim EV, Mamanova LB, Maripov R, Kojonazarov BK, Mirrakhimov MM, Wilkins MR, Morrell NW. Characterization of high-altitude pulmonary hypertension in the Kyrgyz: association with angiotensin-converting enzyme genotype. Am J Respir Crit Care Med. 2002;166:1396-1402.
88. Ahsan A, Mohd G, Norboo T, Baig MA, Pasha MAQ. Heterozygotes of NOS3 polymorphisms contribute to reduced nitrogen oxides in high-altitude pulmonary edema. Chest. 2006;130:1511-1519.
89. Rajput C, Najib S, Norboo T, Afrin F, Qadar Pasha MA. Endothelin-1 gene variants and levels associate with adaptation to hypobaric hypoxia in high-altitude natives. Biochem Biophys Res Commun. 2006;341:1218-1224.
90. Rupert JL, Hochachka PW. Genetic approaches to understanding human adaptation to altitude in the Andes. J Exp Biol. 2001;204:3151-3160.
91. Essop MR, Nkomo VT. Rheumatic and nonrheumatic valvular heart disease: epidemiology, management, and prevention in Africa. Circulation. 2005;112:3584-3591.
92. Kumar RK, Tynan MJ. Catheter interventions for congenital heart disease in third world countries. Pediatr Cardiol. 2005;26:241-249.
93. Saxena A. Congenital heart disease in India: a status report. Indian J Pediatr. 2005;72:595-598.
94. Davies H, Deuchar DC, Missen GA. Endomyocardial fibrosis: two cases with severe pulmonary hypertension presenting in England. Guys Hosp Rep. 1965;114:337-362.
95. Ribeiro PA, Muthusamy R, Duran CM. Right-sided endomyocardial fibrosis with recurrent pulmonary emboli leading to irreversible pulmonary hypertension. Heart. 1992;68:326-329.
96. Havron MD Jr. Diet drugs and pulmonary hypertension. J Fam Pract. 1996;43:434-435.
97. Alonso-Ruiz A, Calabozo M, Perez-Ruiz F, Mancebo L. Toxic oil syndrome: a long-term follow-up of a cohort of 332 patients. Medicine (Baltimore). 1993;72:285-295.
98. Kay JM, Heath D. Crotalaria Spectabilis: The Pulmonary Hypertension Plant: Springfield, Ill: CC Thomas; 1969.
99. Behera D, Chakrabarti T, Khanduja KL. Effect of exposure to domestic cooking fuels on bronchial asthma. Indian J Chest Dis Allied Sci. 2001;43:19-25.